• In late February 2026, Hims & Hers Health reported fourth-quarter 2025 results showing higher sales year on year but slightly lower quarterly profit, issued softer-than-expected Q1 2026 revenue guidance amid regulatory and legal pressure on its compounded semaglutide weight-loss offerings, and filed a US$176.23 million shelf registration tied to an ESOP-related Class A share offering.
• The company’s outlook now hinges on how it manages FDA scrutiny, a Novo Nordisk patent lawsuit, an SEC investigation into its GLP-1 disclosures, and the planned acquisition of digital health provider Eucalyptus to expand internationally beyond weight loss.
• We’ll now examine how softer Q1 2026 revenue guidance tied to compounded semaglutide restrictions could reshape Hims & Hers Health’s investment narrative.

The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers Health today, you have to believe its broader telehealth platform and subscription model can stay resilient even as weight loss faces pressure. The key near term catalyst is whether management can stabilize revenue after its softer Q1 2026 outlook tied to compounded semaglutide, while the biggest risk is intensifying regulatory and legal scrutiny of its GLP 1 offerings, including the FDA, SEC and Novo Nordisk actions.

The most relevant development to watch here is the Q1 2026 revenue guidance of US$600 million to US$625 million, which the company linked to a roughly US$65 million headwind from compounded semaglutide shipping restrictions. That same update also outlined full year 2026 revenue guidance of US$2.7 billion to US$2.9 billion, setting a reference point investors can use to judge how much any further GLP 1 disruption affects both short term sentiment and the longer term diversification story.

Yet beneath the growth story, investors should be aware of how the SEC investigation into GLP 1 disclosures could...

Hims & Hers Health's narrative projects $3.3 billion revenue and $261.3 million earnings by 2028. This requires 18.3% yearly revenue growth and about a $67.7 million earnings increase from $193.6 million today.

Uncover how Hims & Hers Health's forecasts yield a $44.36 fair value, a 180% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were penciling in roughly US$4.1 billion of revenue and US$331.6 million of earnings by 2028, painting a far more upbeat picture than consensus that hinges on powerful lab testing and compounding catalysts, but the latest compounded semaglutide setbacks show how quickly those narratives, and the risks you focus on, may need to shift.

Explore 60 other fair value estimates on Hims & Hers Health - why the stock might be worth over 10x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Looking For Alternative Opportunities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
• Capitalize on the AI infrastructure supercycle with our selection of the 33 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.